» Articles » PMID: 19563503

Insulin Resistance is a Major Determinant of Liver Stiffness in Nondiabetic Patients with HCV Genotype 1 Chronic Hepatitis

Overview
Date 2009 Jul 1
PMID 19563503
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In patients with chronic hepatitis C (CHC), liver stiffness measurement (LSM) by transient elastography (TE), is closely related to the stage of fibrosis, but may be affected by necroinflammation. Other factors, such as insulin resistance (IR), might influence the performance of LSM.

Aims: To evaluate in a cohort of nondiabetic patients with genotype 1 CHC, whether IR and other anthropometric, biochemical, metabolic and histological factors contribute to LSM and to identify the best cut-off values of LSM for predicting different stages of fibrosis.

Methods: Nondiabetic patients with genotype 1 CHC (n = 156) were evaluated by liver biopsy (Metavir score), anthropometric, biochemical and metabolic features including IR. Furthermore, all subjects underwent LSM by TE.

Results: Severe fibrosis (F3-F4) was associated with LSM (OR 1.291; 95%CI 1.106-1.508). LSM was also independently correlated with low platelets (P = 0.03), high gammaGT (P < 0.001) and high HOMA (P = 0.004) levels. A stiffness value > or =8 KPa was identified as the best cut-off for predicting severe fibrosis (AUC 0.870); yet this cut-off still failed to rule out F3-F4 fibrosis in 22.7% of patients (false-negative rate) or rule in F3-F4 in 19.6% (false-positive rate). Platelets <200 x 10(3)/mmc and a HOMA of >2.7 were the major determinants of these diagnostic errors in predicting severe fibrosis. Conclusions In nondiabetic patients with genotype 1 CHC, insulin resistance, gammaGT and platelet levels contribute to LSM independently of liver fibrosis. The identification of these three factors contributes to a more correct interpretation of LSM.

Citing Articles

Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.

Lee M, Chen W, Hsu W, Chen S, Lee J Int J Mol Sci. 2019; 20(18).

PMID: 31540136 PMC: 6769880. DOI: 10.3390/ijms20184569.


Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.

Li X, Jiao Y, Xing Y, Gao P Biomed Res Int. 2019; 2019:5308308.

PMID: 31080822 PMC: 6475555. DOI: 10.1155/2019/5308308.


Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C.

Bering T, Diniz K, Coelho M, Vieira D, Soares M, Kakehasi A J Cachexia Sarcopenia Muscle. 2018; 9(2):255-268.

PMID: 29349902 PMC: 5879980. DOI: 10.1002/jcsm.12269.


Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.

Desbois A, Cacoub P World J Gastroenterol. 2017; 23(9):1697-1711.

PMID: 28321170 PMC: 5340821. DOI: 10.3748/wjg.v23.i9.1697.


Systemic manifestations of hepatitis C infection.

Tang L, Marcell L, Kottilil S Infect Agent Cancer. 2016; 11:29.

PMID: 27222662 PMC: 4878040. DOI: 10.1186/s13027-016-0076-7.